Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2015

The following common equivalent shares were not included in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands):

	Year Ended December 31,
	2015(1)		2014		2013
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan		5,290		6,239		4,095
Unvested RSAs		1,644		1,772		2,364
Shares issuable upon conversion of convertible subordinated notes		12,904		12,329		2,780

Total		19,838		20,340		9,239

(1)

Includes 4.1 million options, 0.4 million restricted stock units, and 1.0 million unvested RSAs retained by former employees who were transferred to Theravance Biopharma in connection with the Spin-Off during the year ended December 31, 2015. Subsequent to the Spin-Off, stock-based compensation expense associated with the awards held by Theravance Biopharma employees granted prior to the Spin-Off is recognized by Theravance Biopharma.